Valuation: Proteome Sciences plc

Market Cap 49.8L 65.77L 58.77L 54.83L 93.8L 64Cr 94.5L 6.59Cr 2.57Cr 32Cr 2.47Cr 2.42Cr 104.02Cr P/E 2024
-2.95x
P/E 2025 -2.4x
Enterprise Value 2Cr 2.64Cr 2.36Cr 2.2Cr 3.76Cr 255.12Cr 3.79Cr 26Cr 10Cr 129.75Cr 9.9Cr 9.69Cr 417.1Cr EV / Sales 2024
4.79x
EV / Sales 2025 5.96x
Free-Float
81.48%
Yield 2024 *
-
Yield 2025 -
1 day-10.40%
3 months-54.75%
6 months-54.75%
Current year-70.72%
Current year 0.01
Extreme 0.0112
0.03
1 year 0.01
Extreme 0.0112
0.04
3 years 0.01
Extreme 0.0112
0.08
5 years 0.01
Extreme 0.0112
0.18
10 years 0.01
Extreme 0.0112
0.18
Manager TitleAgeSince
Corporate Officer/Principal - 01/04/2017
Corporate Secretary - 01/08/2017
Director TitleAgeSince
Chairman 73 30/06/2014
Director/Board Member 62 01/01/2010
Director/Board Member 71 01/07/2014
Change 5-day change 1-year change 3-year change Capi.($)
-10.40%-.--% - - 67.77L
+0.32%-0.07%-25.76%+2.07% 17TCr
-1.66%-0.68%-12.84%+14.07% 11TCr
-0.93%+0.51%-25.04%+3.74% 11TCr
-0.03%+1.42%-46.89%-10.61% 7.6TCr
-0.10%+5.80%+2.90%+70.62% 6.04TCr
-0.65%+6.59%+11.44%+66.40% 5.35TCr
-0.71%+0.98%-6.11%-31.99% 4.91TCr
-1.82%-2.78%-19.07%+14.79% 4.06TCr
+0.70%-2.13%+27.90%+1.64% 3.15TCr
Average -1.52%+0.24%-10.39%+14.52% 7.77TCr
Weighted average by Cap. -0.50%-0.05%-16.38%+12.03%

Financials

2024 2025
Net sales 48.87L 64.54L 57.67L 53.8L 92.04L 62Cr 92.73L 6.47Cr 2.53Cr 32Cr 2.42Cr 2.37Cr 102.08Cr 37.56L 49.61L 44.32L 41.35L 70.74L 48Cr 71.27L 4.97Cr 1.94Cr 24Cr 1.86Cr 1.82Cr 78Cr
Net income -34.06L -44.98L -40.19L -37.5L -64.15L -44Cr -64.63L -4.51Cr -1.76Cr -22Cr -1.69Cr -1.65Cr -71Cr -30.61L -40.43L -36.12L -33.7L -57.65L -39Cr -58.08L -4.05Cr -1.58Cr -20Cr -1.52Cr -1.48Cr -64Cr
Net Debt 1.34Cr 1.77Cr 1.58Cr 1.47Cr 2.52Cr 171.12Cr 2.54Cr 18Cr 6.92Cr 87Cr 6.64Cr 6.5Cr 279.76Cr 1.5Cr 1.98Cr 1.77Cr 1.65Cr 2.82Cr 191.5Cr 2.84Cr 20Cr 7.75Cr 97Cr 7.43Cr 7.27Cr 313.08Cr
Projected Income Statement - Annual - Proteome Sciences plc
Logo Proteome Sciences plc
Proteome Sciences plc is a specialist provider of contract proteomics services. The Company’s services enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic and therapeutic applications. SysQuant and TMT MS2 are unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents for multiplex quantitative proteomics.
Employees
32